Neyt Mattias, Christiaens Thierry, Demotes Jacques, Walley Tom, Hulstaert Frank
Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.
Ghent University, Belgium.
J Comp Eff Res. 2016 Nov;5(6):551-560. doi: 10.2217/cer-2016-0018. Epub 2016 Sep 5.
Many questions of relevance to patients/society are not answered by industry-sponsored clinical trials. We consider whether there are benefits to governments in funding practice-oriented clinical trials.
A literature search including publications on institutions' websites was performed and supplemented with information gathered from (inter)national stakeholders.
Areas were identified where public funding of clinical trials is of importance for society, such as head-to-head comparisons or medical areas where companies have no motivation to invest. The available literature suggests publicly funded research programs could provide a positive return on investment. The main hurdles (e.g., sufficient funding and absence of equipoise) and success factors (e.g., selection of research questions and research infrastructure) for the successful conduct of publicly funded trials were identified.
Governments should see public funding of pragmatic practice-oriented clinical trials as a good opportunity to improve the selection and quality of treatments and stimulate efficient use of limited resources.
制药企业赞助的临床试验并未回答许多与患者/社会相关的问题。我们探讨政府资助以实践为导向的临床试验是否有好处。
进行了文献检索，包括机构网站上的出版物，并补充了从（国际）利益相关者收集的信息。
确定了临床试验的公共资助对社会至关重要的领域，例如头对头比较或公司没有投资动机的医疗领域。现有文献表明，公共资助的研究项目可以提供积极的投资回报。确定了成功开展公共资助试验的主要障碍（例如，资金充足和缺乏均衡性）和成功因素（例如，研究问题的选择和研究基础设施）。
政府应将公共资助务实的以实践为导向的临床试验视为改善治疗选择和质量以及促进有限资源有效利用的好机会。
